Company profile: NeuMoDx Molecular
1.1 - Company Overview
Company description
- Provider of molecular diagnostic (MDx) testing solutions for hospital and clinical reference laboratories, including fully automated, continuous random-access analyzers (NeuMoDx 288 and 96) that integrate sample-to-result using proprietary NeuDry reagent technology, plus lysis buffers (3 and 4), an HBV quant test strip, and a GBS assay.
Products and services
- NeuMoDx 288 Molecular System: An industrial-grade, fully automated, continuous random-access analyzer integrating the entire molecular diagnostic process from sample to result, utilizing proprietary NeuDry reagent technology
- NeuMoDx 96 Molecular System: A smaller-scale, fully automated, continuous random-access analyzer that integrates the entire molecular diagnostic process from sample to result, utilizing proprietary NeuDry reagent technology
- NeuMoDx GBS Assay: A laboratory-grade assay engineered to detect Group B Streptococcus (GBS) DNA in antepartum pregnant women.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to NeuMoDx Molecular
ArcticZymes Technologies
HQ: Norway
Website
- Description: Provider of enzymes and kits for medical research, developed and manufactured by a biotechnology company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ArcticZymes Technologies company profile →
Cryoniss
HQ: United Kingdom
Website
- Description: Provider of temperature-controlled biobanking and cold-chain logistics for life sciences, offering regulated storage of human biological samples at vapour phase liquid nitrogen, -80°C, -20°C, +4°C and ambient; cell banking and culture with next-day dispatch; bioreagents storage with cloud-based traceability; cell line QC testing via preferred suppliers; end-to-end sample transport; and access to samples for research.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cryoniss company profile →
Singulex
HQ: United States
Website
- Description: Provider of direct molecular detection and cardiovascular monitoring solutions, including the Singulex Clarity System, an automated in vitro diagnostics platform using Single Molecule Counting technology for precise, ultra-low-level biomarker measurement across a 6-log reporting range, and the Singulex cTnI Assay for femtogram-per-milliliter cardiac troponin I quantitation to aid cardiovascular disease diagnosis and management.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Singulex company profile →
Culture Biosciences
HQ: United States
Website
- Description: Provider of cloud-connected bioreactors and Console software enabling remote, real-time design, monitoring, and analysis of cell culture and bioprocess experiments, plus bioprocess development services including clone screening, process characterization, media screening, and process optimization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Culture Biosciences company profile →
Intelligent BioSystems
HQ: United States
Website
- Description: Provider of an advanced DNA sequencing system, focused on commercialization. Founded in 2005 by Drs. Steven J. Gordon and Jingyue Ju, the company builds on Dr. Gordon’s prior role founding Intelligent Automation Systems, which delivered key instrumentation solutions that helped complete the Human Genome Project.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Intelligent BioSystems company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for NeuMoDx Molecular
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to NeuMoDx Molecular
2.2 - Growth funds investing in similar companies to NeuMoDx Molecular
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for NeuMoDx Molecular
4.2 - Public trading comparable groups for NeuMoDx Molecular
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →